These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 39348984)

  • 1. Systemic Inflammation Indexes and Risk of Immune-related Adverse Events in Patients With Metastatic Urothelial Carcinoma Treated With Immunotherapy.
    Dionese M; Bimbatti D; Pierantoni F; Lai E; Erbetta E; Cavasin N; Jubran S; Basso U; Maruzzo M
    Anticancer Res; 2024 Oct; 44(10):4379-4386. PubMed ID: 39348984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
    Tural D; Arslan C; Selcukbiricik F; Olmez OF; Erman M; Ürün Y; Erdem D; Kilickap S
    Clin Genitourin Cancer; 2024 Oct; 22(5):102163. PubMed ID: 39126823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic role of circulating cytokines and inflammation indexes for avelumab maintenance in metastatic urothelial carcinoma.
    Maiorano BA; Schinzari G; Carbone C; Piro G; Rossi E; Di Maio M; Di Giacomo A; Maiello E
    Front Immunol; 2024; 15():1401214. PubMed ID: 38799450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy.
    Yang M; Zhang J; Wei D; Yu T; Chen Z; Liu X; Zhu H
    BMC Cancer; 2024 Feb; 24(1):196. PubMed ID: 38347460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Zhang Y; Chen J; Liu H; Dai J; Zhao J; Zhu S; Zhang X; Liang J; Hu X; Zhao J; Liu Z; Shen P; Sun G; Zeng H
    Cancer Treat Rev; 2024 Sep; 129():102787. PubMed ID: 38905806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Serum Magnesium Levels and Outcomes of Atezolizumab in Patients With Metastatic Urothelial Carcinoma.
    Fukuokaya W; Akazawa K; Kimura T
    Anticancer Res; 2024 May; 44(5):2117-2123. PubMed ID: 38677745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of immunotherapy-induced inflammation indexes: dynamic changes in patients with nasopharyngeal carcinoma receiving immune checkpoint inhibitors.
    Cao J; Chen Q; Bai X; Liu L; Ma W; Lin C; Lu F; Zhou T; Zhan J; Huang Y; Yang Y; Luo F; Zhao H
    Ann Med; 2023; 55(2):2280002. PubMed ID: 38065623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment.
    Hirasawa Y; Kubota Y; Mura E; Suzuki R; Tsurui T; Iriguchi N; Ishiguro T; Ohkuma R; Shimokawa M; Ariizumi H; Horiike A; Wada S; Ariyoshi T; Goto S; Otsuka K; Murakami M; Kiuchi Y; Yoshimura K; Hoffman RM; Tsunoda T
    Anticancer Res; 2024 Aug; 44(8):3397-3407. PubMed ID: 39060084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma.
    Vanguri RS; Smithy JW; Li Y; Zhuang M; Maher CA; Aleynick N; Peng X; Al-Ahmadie H; Funt SA; Rosenberg JE; Iyer G; Bajorin D; Mathews JC; Nadeem S; Panageas KS; Shen R; Callahan MK; Hollmann TJ
    J Pathol; 2023 Nov; 261(3):349-360. PubMed ID: 37667855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment.
    Morales-Barrera R; Villacampa G; Vidal N; Figols M; Giner J; Bonfill T; Suárez C; Díaz N; Mateo J; González M; Domenech M; Puente J; Carles J
    Clin Transl Oncol; 2023 Dec; 25(12):3556-3564. PubMed ID: 37217634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC).
    Palacka P; Slopovsky J; Obertova J; Chovanec M; Rejlekova K; Sycova-Mila Z; Kollarik B; Mardiak J; Mego M
    Anticancer Res; 2021 Nov; 41(11):5749-5759. PubMed ID: 34732448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of near-term prediction models for severe immune-related adverse events in malignant tumor PD-1 inhibitor therapy.
    Du Y; Zhang Y; Zhao W; Zhang Y; Su F; Zhang X; Li W; Hu W; Li Y; Zhao J
    Hum Vaccin Immunother; 2024 Dec; 20(1):2398309. PubMed ID: 39267589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of Nutritional Markers as Predictors After Immunotherapy in Advanced Head and Neck Squamous Cell Carcinoma.
    Matsumura S; Kaira K; Kuba K; Inoue H; Hamada M; Yamazaki T; Nakahira M; Ebihara Y
    Anticancer Res; 2024 Sep; 44(9):4049-4056. PubMed ID: 39197909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events.
    Nizam A; Rader RK; Tzeng A; Wei W; Sheng IY; Martin A; Wee CE; Gilligan TD; Gupta S; Ornstein MC
    Clin Genitourin Cancer; 2024 Apr; 22(2):368-379. PubMed ID: 38245437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer.
    Gómez de Liaño Lista A; van Dijk N; de Velasco Oria de Rueda G; Necchi A; Lavaud P; Morales-Barrera R; Alonso Gordoa T; Maroto P; Ravaud A; Durán I; Szabados B; Castellano D; Giannatempo P; Loriot Y; Carles J; Anguera Palacios G; Lefort F; Raggi D; Gross Goupil M; Powles T; Van der Heijden MS
    Eur Urol; 2020 Feb; 77(2):269-276. PubMed ID: 31699525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma.
    Dharmapuri S; Özbek U; Jethra H; Jun T; Marron TU; Saeed A; Huang YH; Muzaffar M; Pinter M; Balcar L; Fulgenzi C; Amara S; Weinmann A; Personeni N; Scheiner B; Pressiani T; Navaid M; Bengsch B; Paul S; Khan U; Bettinger D; Nishida N; Mohamed YI; Vogel A; Gampa A; Korolewicz J; Cammarota A; Kaseb A; Galle PR; Pillai A; Wang YH; Cortellini A; Kudo M; D'Alessio A; Rimassa L; Pinato DJ; Ang C
    World J Gastrointest Oncol; 2023 Nov; 15(11):1900-1912. PubMed ID: 38077640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.